Aurobindo PharmaBOM:524804 -1.38%88 Pretax Margin % is 14.75% as of Mar. 2026, which is 8% below its 10-year median of 16.12. GuruFocus rates BOM:524804 with a GF Score™ of 88/100 and a GF Value™ of ₹1,333.66 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 961 Drug Manufacturers companies, Aurobindo Pharma ranks better than 70.97% on this metric.
The historical rank and industry rank for Aurobindo Pharma's Pretax Margin % or its related term are showing as below:
BOM:524804'
s Pretax Margin % Range Over the Past 10 Years
Min: 10.61 Med: 16.12 Max: 29.9
Current: 15.31
BOM:524804's Pretax Margin % is ranked better than 70.97% of 961
companies
in the Drug Manufacturers industry
Industry Median: 7.28
vs BOM:524804: 15.31
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Aurobindo Pharma Pretax Margin % Related Terms
Aurobindo Pharma Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Aurobindo Pharma's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524804 vs ZTS, UTHR: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Aurobindo Pharma's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aurobindo Pharma Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aurobindo Pharma's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Aurobindo Pharma's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aurobindo Pharma (BOM:524804) has a Pretax Margin % of 14.75% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Aurobindo Pharma and its competitors. This is near median its historical median of 16.12. Over the past decade, Aurobindo Pharma's Pretax Margin % has ranged from 10.61 to 29.90. According to the industry distribution chart, Aurobindo Pharma ranks #279 out of 961 companies in the Drug Manufacturers industry, placing it in the top 29%.
Is Aurobindo Pharma's Pretax Margin % too high?
Aurobindo Pharma's current Pretax Margin % of 14.75% is near median its 10-year median of 16.12. Over the past 10 years, this metric has ranged from a low of 10.61 to a high of 29.90. The Drug Manufacturers industry median Pretax Margin % is 7.28. Aurobindo Pharma's value of 14.75% is 102.6% above this industry median. Based on the distribution chart, Aurobindo Pharma ranks #279 out of 961 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Aurobindo Pharma has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aurobindo Pharma's Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Aurobindo Pharma ranks #279 out of 961 companies for Pretax Margin %. This puts Aurobindo Pharma in the upper half of its industry. The industry median Pretax Margin % is 7.28. Aurobindo Pharma's value of 14.75% is 102.6% above this benchmark. Historically, Aurobindo Pharma's own Pretax Margin % has ranged from 10.61 to 29.90 over the past decade. While the company's 10-year median is 16.12 vs. the industry median of 7.28, Aurobindo Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.28, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aurobindo Pharma's current Pretax Margin % of 14.75% is 102.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Aurobindo Pharma and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aurobindo Pharma's current Pretax Margin % is 14.75%, which is near median its own 10-year median of 16.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurobindo Pharma stock overvalued right now?
Based on GuruFocus' analysis, Aurobindo Pharma (BOM:524804) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,333.66, compared to a current price of ₹1,564.65 — trading 17.3% above its estimated fair value. The current Pretax Margin % is 14.75%, which is near median its 10-year median of 16.12 and 102.6% above the Drug Manufacturers industry median of 7.28. Aurobindo Pharma's overall GF Score™ is 88/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Aurobindo Pharma (BOM:524804), the current Pretax Margin % is 14.75% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aurobindo Pharma (BOM:524804) Overvalued in 2026?
Based on GuruFocus' analysis, Aurobindo Pharma stock appears to be overvalued.
The current stock price of ₹1,564.65 is trading 17.3% above its estimated GF Value™ of ₹1,333.66.
GuruFocus considers Aurobindo Pharma to be Modestly Overvalued.
Key valuation signals for BOM:524804:
Pretax Margin %: 14.75% (near median its 10-year median of 16.12)
GF Value™: ₹1,333.66 vs. price of ₹1,564.65 (17.3% above fair value)
Industry Position: 102.6% above the Drug Manufacturers median (#279 of 961)
No single metric tells the full story. See the BOM:524804 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aurobindo Pharma Ltd is a specialty and generic drug manufacturing company. It is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Its formulations target key therapeutic areas, including Central Nervous System (CNS), Antibiotics, Anti-diabetics, Cardiovascular, Anti-retroviral, Gastroenterology, Oncology, and Dermatology. The operating and reportable segments of the company are; India, the United States of America, Europe, and the Rest of the World. The company generates a majority of its revenue from its business in the United States of America.
88GF Score
Get the complete analysis for BOM:524804
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524804 has been successfully added to your 
